Your session was unable to be renewed and will be expiring in 0 seconds.
Click here to attempt to renew your session.
Southeast Missouri State 84, Cal Poly 68
FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
Back
![Loading... [Loading...]](https://media-sixrivers.mynews360.com/images/loading.gif)